close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.590 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market ↗
Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗
These aren't for the faint of heart. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation. 
Via The Motley Fool
Topics Artificial Intelligence
Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss ↗
Via Chartmill
Recursion Pharmaceuticals (NASDAQ:RXRX) Soars on Q4 Earnings Beat ↗
Via Chartmill
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
The stock looks cheap, but appearances can be deceiving. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
A Deep Dive Into NVIDIA’s Latest Portfolio Moves ↗
NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example. 
Via MarketBeat
Topics Artificial Intelligence Economy Regulatory Compliance
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
Via Investor Brand Network
Topics Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗
The old healthcare model is breaking down. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Future of Intoxication Detection May Be in Your Voice
From BioMedWire
Via GlobeNewswire
News headline image
Recursion (RXRX) Q1 2026 Earnings Transcript ↗
Recursion (RXRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Reports First Quarter Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces Board Transition
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
1 Beaten-Down AI Stock to Buy and 1 to Avoid ↗
One of these is not like the other. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
From Citeline
Via GlobeNewswire
News headline image
2 AI Healthcare Stocks to Buy Right Now ↗
The convergence of two already fantastic industries is creating an incredible opportunity. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 ↗
The sweeping correction that most of these stocks have suffered was not only predictable, but it also reliably precedes a better-supported recovery. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years. ↗
AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Can This AI Stock Bounce Back in 2026? ↗
It's not looking too good for the biotech. 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Recursion (RXRX) Q4 2025 Earnings Call Transcript ↗
Recursion (RXRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
What's Behind The Jump In Recursion Pharmaceuticals Stock? ↗
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell. 
Via Benzinga
News headline image
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗
Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin. 
Via Stocktwits
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.